ArticleFrontiers in psychiatry2026
Case Report: Trazodone as a possible treatment for psychiatric adverse events related to ALK inhibitors.
Article in Frontiers in psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Lorlatinib is a third-generation tyrosine kinase inhibitor approved for the first-line treatment of ALK-positive metastatic non-small cell lung cancer, frequently associated with psychiatric adverse events. Method: This study presents the clinical case of a patient who was successfully treated with low-dose trazodone for lorlatinib-induced psychiatric symptoms. In addition, an overview of the existing literature on the management of psychiatric adverse events (AEs) associated with ALK inhibitors is provided. Results and conclusions: Based on the evidence presented and the preliminary outcomes observed in the reported case, this study aims to outline a management strategy for lorlatinib-related psychiatric complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.